All News

Article

Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab

Meral K. El Ramahi, MD, FACP, FACR Nov 14, 2023

Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated.

Article

Urinary biomarkers precede loss of kidney function for lupus nephritis

Eric Dein, MD Nov 14, 2023

In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.

Article

Effective Treatments for Rheumatoid Arthritis ILD

Michael Putman, MD, MSCI Nov 14, 2023

The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.

Pregnancies outcomes in vasculitis: - Higher frequency of spontaneous abortion and preterm delivery - 12% had pre-eclampsia - Risk higher in multiparous > nalliparous - Risk highest in small vessel vasculitis Rector A, Abst#2425 #ACR23 #ACRBest @RheumNow https://t.co/TgbRWw9il5

Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU CAN Lupus flare risk index calculated prior to disease activity change or stable pt. Results combined for score 11 mediators #ACR23 @RheumNow @ACRheum abst#2554 https://t.co/gUimJLrJ33

Body mass is associated w/ ttmt response in RA Data from RACAT & TEAR studies TNFi > triple th in underweight gpe but not in overweight gpe Similar result in gpe w/ low leptin levels & low adipokine scores True biology or confounding bias? @RheumNow #ACR23 ABST2541 https://t.co/OhKj6QNaSa

Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better response to TNFi, overweight/obese respond equally to both. Abstr#2541 #ACR23 @RheumNow https://t.co/SROD3esMCD https://t.co/ni3I8tD7wI

Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux? Antibody titres better when not getting regular ritux around boosters Maybe boosters 9mo (or so) gap after ritux helps immunogenicity @TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx

The Lupus APOL1 Story Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23 https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4

The Lupus APOL1 Story | RheumNow

ROMO vs DEN. Romosozumab was superior to denosumab (ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) in raising the spine BMD but not in hip at month 12 in chronic GC users with high fracture risk Mok C Abst#242 #ACR23 @RheumNow https://t.co/q2OKD6C2Me

Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR

Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly. Gene expression signatures might tell us more - one key cluster here was 21x predictive. #ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC

#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE

During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations. ⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM ➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum

HCQ and risk of retinopathy 👁️ DoD database HCQ 44000+ females & 10000+ males Risk retinopathy HR 1.5 Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7 No adjustment on HCQ dose @RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45

@md_chawla @RheumNow https://t.co/PVxox5t8ZH

@md_chawla @RheumNow https://t.co/qSdT7by1Vh

Erosive hand #OA may be more painful than treated #RA patients. The burden of OA is often not alked about, and this study highlights it! @RheumNow #ACR23 https://t.co/jLbvtMmgE0

#ACR23 Abstr# 2489 I can’t wait for Phase 3 RCT results as I have many #SLE patients with refractory cutaneous lupus. Post-hoc analyses of Phase 2 RCT of Deucravacitinib showed its efficacy (CLASI-50) over PBO across all CLE subtypes @RheumNow https://t.co/G7edkAU18J

And to continue B-SAFE Clinical risk score for HCQ retinopathy 👁️ 10 years 4000+ pts, 3% retinopathy over 5yrs Predictors of HCQ retinopathy -body weight -sex -age -eGFR -weight based dose mg/kg -higher cumulative dose Risk ranges 1% to >20% @RheumNow #ACR23 ABST2453 https://t.co/h2tl6vH9M3 https://t.co/8iuRxoVaJ0

Topics

All News

Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab

Urinary biomarkers precede loss of kidney function for lupus nephritis

Effective Treatments for Rheumatoid Arthritis ILD

Do you get our email newsletter?